Sign in

    Hannah Hefley

    Senior Research Associate at Stephens

    Hannah Hefley is a Senior Research Associate at Stephens, specializing in equity research for the life science tools and pharma services sector. She covers companies within these industries and supports senior analysts with financial modeling, industry analysis, and investment recommendations, though specific company names and performance metrics are not publicly available. Hefley began her career in financial services in 2023 and holds an MBA in Finance and Accounting, operating from the firm's Little Rock, Arkansas office. Her professional credentials include industry-standard education in finance, but no evidence of FINRA licenses or notable investment performance records have been published.

    Hannah Hefley's questions to MAXCYTE (MXCT) leadership

    Hannah Hefley's questions to MAXCYTE (MXCT) leadership • Q2 2025

    Question

    Hannah Hefley asked to quantify the benefit from the Processing Assembly (PA) revenue pull-forward due to tariffs and whether PA revenue would consequently step down. She also questioned if the previously insulated SPL customers were now seeing broader impacts from macro headwinds, affecting the SPL pipeline.

    Answer

    CFO Douglas Swirsky explained the PA revenue benefit was from a single distributor order and is already factored into guidance without an expected material future impact. President and CEO Maher Masoud stated the SPL pipeline remains strong, with a target of 3-5 new deals annually. He emphasized that while four programs were shut down, four new ones were added, maintaining 18 total clinical programs, a dynamic that is built into their business model.

    Ask Fintool Equity Research AI

    Hannah Hefley's questions to Azenta (AZTA) leadership

    Hannah Hefley's questions to Azenta (AZTA) leadership • Q3 2025

    Question

    Hannah Hefley from Stephens Inc. asked for more details on the headwinds in gene synthesis, specifically the cause of softness from key pharma accounts and the expected timeline for resolution.

    Answer

    CEO John Marotta explained that the softness in gene synthesis is due to project timing delays within North American pharma accounts. He indicated that the issue is related to timing rather than a fundamental shift and noted that the company is already seeing 'green shoots' of recovery for Q4.

    Ask Fintool Equity Research AI

    Hannah Hefley's questions to 908 Devices (MASS) leadership

    Hannah Hefley's questions to 908 Devices (MASS) leadership • Q3 2024

    Question

    Hannah Hefley, on for Jacob Johnson, asked how partnerships with hardware innovators in the cell and gene therapy market are expected to drive desktop growth and if initial contributions could be quantified. She also asked for an update on the competitive landscape for desktops and current trends in consumable pull-through.

    Answer

    Executive Kevin Knopp explained that strategic partnerships are a long-term strategy to scale the desktop business efficiently, noting that about half of the anticipated Q4 desktop orders are a result of these collaborations. He stated there has been no change in the competitive landscape, with demand challenges being macro-driven. Executive Joseph Griffith added that desktop recurring revenue was approximately $2 million for the quarter, and consumable utilization for desktops has remained consistent at about half a kit per month for active users.

    Ask Fintool Equity Research AI

    Hannah Hefley's questions to BIO-TECHNE (TECH) leadership

    Hannah Hefley's questions to BIO-TECHNE (TECH) leadership • Q2 2024

    Question

    Hannah Hefley, on for Jacob Johnson, asked for quantification of the benefit from large cell therapy orders and clarification on whether recent instrument growth was from new placements or consumables.

    Answer

    CEO Kim Kelderman highlighted that the number of customers in clinical trials grew to 85, driving larger orders and a 40% trailing 12-month growth in GMP reagents. CFO Jim Hippel quantified the Q2 benefit at about 2 percentage points of total company growth. Kelderman confirmed the instrument growth was from new placements, marking a positive turn for the installed base.

    Ask Fintool Equity Research AI